Lessons from ONTARGET

Acta Clinica Belgica
V BerlaimontA G Herman

Abstract

The recently published results of the ONTARGET trial shed a new light on the cardiovascular protection of patients at high risk of a cardiovascular event. Despite a number of trials looking at the efficacy of Angiotensin Converting Enzyme inhibitors (ACEis) or Angiotensin Receptor Blockers (ARBs) in the prevention of cardiovascular events in patients with specific high risk profiles, the question of the equivalence of ACEis and ARBs remained unanswered. The ONTARGET trial has shown that telmisartan 80 mg administered for a median duration of 4.5 years to patients at high risk of developing a major cardiovascular event, is equally effective to ramipril 10 mg. In addition, telmisartan was slightly better tolerated. The comparator ramipril has been chosen as it is currently the gold standard ACEi since the results of the HOPE study, in terms of the composite outcome of cardiovascular death, myocardial infarction and stroke. Moreover, ONTARGET is the first trial to test the hypothesis of superiority of adding an ARB (telmisartan 80 mg) to an ACEi (ramipril 10 mg) over the ACEi ramipril monotherapy in cardiovascular protection of the same broad range of high-risk patients. Surprisingly, despite a more pronounced blood pressure lower...Continue Reading

References

Sep 16, 1992·Biochemical and Biophysical Research Communications·B KimuraM I Phillips
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·M NakajimaV J Dzau
Sep 1, 1996·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·R B DevereuxM J Roman
Jan 1, 1997·Clinical Cardiology·M I Oliverio, T M Coffman
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Feb 24, 2001·Cellular and Molecular Life Sciences : CMLS·R LuciusT Unger
Jan 11, 2002·Lancet·P SleightUNKNOWN Heart Outcomes Prevention Evaluation (HOPE) Study
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Aug 2, 2003·Lancet·Majid EzzatiUNKNOWN Comparative Risk Assessment Collaborating Group
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Jun 3, 2004·JAMA : the Journal of the American Medical Association·Derek YachKaren J Hofman
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
May 4, 2005·Acta Diabetologica·P Sleight
Jul 27, 2005·Peptides·U M SteckelingsTh Unger
Sep 15, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Jan A StaessenJi-Guang Wang
Dec 23, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Pantelis A SarafidisGeorge L Bakris
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.